Who actually makes compounded peptides? The supply chain
Most people assume a pharmacy makes everything from scratch. The reality involves several stops — and knowing each one helps you ask better questions about quality.
TL;DR
- The compounded peptide supply chain starts with a raw ingredient maker, not the pharmacy.
- CDMOs — Contract Development and Manufacturing Organizations — often produce the API (the active drug powder) before it reaches a pharmacy.
- Two types of pharmacy finish the job: 503A (single-patient) and 503B outsourcing facilities (larger batches, stricter rules).
Who makes compounded peptides
Who makes compounded peptides begins at the ingredient level, not at the pharmacy counter. An ingredient manufacturer produces the API — active pharmaceutical ingredient (in plain English: the actual drug powder). Many of these manufacturers are located overseas. That powder then ships to a licensed US pharmacy. There, it is weighed, mixed, and dispensed as a finished, labeled vial for a specific patient.
What is a CDMO and what role does it play
A CDMO is a Contract Development and Manufacturing Organization. In plain English: an outside factory hired to produce a drug ingredient for another company. CDMOs frequently produce the peptide APIs that pharmacies use. Think of it like a contract bakery. The CDMO supplies the flour and dough. The pharmacy is the kitchen that bakes each loaf to a patient's order. One CDMO may supply dozens of pharmacies at once.
Where do compounded peptides come from before the pharmacy
Where do compounded peptides come from once the API is made? The raw ingredient ships from the CDMO to a licensed compounder in the United States. That compounder must verify the API's identity, purity, and potency before using it. Third-party lab testing is a common way to do this. This verification step — though it cannot by itself confirm a clinical outcome — is one of the primary quality checkpoints in the chain.
The two pharmacy types that finish the compounded peptide supply chain
Two pharmacy models handle the final step. A 503A pharmacy (in plain English: a traditional compounding pharmacy) prepares medication for one specific patient under a valid prescription. A 503B outsourcing facility (in plain English: a higher-volume compounder regulated more like a manufacturer) produces larger batches. The FDA (Food and Drug Administration) publishes a list of registered outsourcing facilities. That list numbered roughly 90 facilities in 2025 (FDA, Registered Outsourcing Facilities, 2025).
Why verification matters at every link
503B outsourcing facilities must follow CGMP — Current Good Manufacturing Practice (in plain English: the FDA's quality rulebook for drug production). The FDA inspects them on a risk-based schedule (FDA, Information for Outsourcing Facilities, 2024). Compounded medications are not FDA-approved. Responsibility for checking each link — ingredient source, accreditation, third-party testing — falls on the pharmacy and the ordering clinician. Patients can ask which CDMO supplied the API and whether a certificate of analysis exists for the batch. Verification, not assumption, is how quality is checked.
Related reading:
- 503A vs 503B compounding: the functional difference
- API standards: what goes into a compounded peptide
- Biosimilars vs generics: what's the difference?
- The FDA 503A bulks list: how a peptide qualifies to be compounded
- How a peptide becomes a prescription medication
FAQ
Q: Who makes compounded peptides? Multiple parties are involved. An ingredient manufacturer — often a CDMO — produces the raw API. A licensed 503A or 503B pharmacy then turns that ingredient into a finished, dosed vial for a patient.
Q: What is a CDMO? A CDMO, or Contract Development and Manufacturing Organization, is an outside factory hired to develop and produce a drug ingredient on behalf of another company. Compounding pharmacies source raw peptide APIs from these suppliers.
Q: Where do compounded peptides come from? Compounded peptides begin as raw API produced by ingredient manufacturers, often overseas CDMOs. That material ships to a licensed US pharmacy, which compounds and dispenses it under a valid prescription.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
Frequently asked questions
Who makes compounded peptides?
Multiple parties are involved. An ingredient manufacturer — often a CDMO — produces the raw API. A licensed 503A or 503B pharmacy then turns that ingredient into a finished, dosed vial for a patient.
What is a CDMO?
A CDMO, or Contract Development and Manufacturing Organization, is an outside factory hired to develop and produce a drug ingredient. Compounding pharmacies source raw peptide APIs from these suppliers.
Where do compounded peptides come from?
Compounded peptides begin as raw API produced by ingredient manufacturers, often overseas CDMOs. That material ships to a licensed US pharmacy, which compounds and dispenses it under a valid prescription.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.